Low-Dose Methotrexate for the Treatment of Inflammatory Knee Osteoarthritis: A Randomized Clinical Trial

Метотрексат в низких дозах для лечения воспалительного остеоартрита коленного сустава
David John Hunter, Flavia Cicuttini, Xiaoxia Li, Xiaofeng Zeng, Zhanguo Li, Yang Xi, Yi Zhao, Zhiyi Zhang, Cibo Huang, Yingjuan Chen, Yifang Mei, Changhai Ding, Jianhua Xu, Weiyu Han, Yunfeng Pan, Xiaotong Zhu, Peihua Cao, Yuan Qu, Zhaohua Zhu, Haowei Chen, Guangfeng Ruan, Qinghong Yu, Xiaomei Leng, Limin Ren, Kun Wang, T W LI, Mei-hua Guan, Jing Wu, Qiuju Liao, Zhe Wang, Zetao Liao, Weiming Deng, Kang Wang, Tingting Zhu, Yuping Zhang, Lixia Gao, Xiaoni Zhou, Yan Zhang, Peichun Gao, Qin Dang
2025-06-02

effusion-synovitisinflammatory knee osteoarthritislow-dose methotrexaterandomized clinical trialvisual analog scale pain
Importance: A recent study reported that methotrexate may reduce joint pain in patients with inflammatory hand osteoarthritis (OA). However, it remains unknown whether methotrexate has similar effects on inflammatory knee OA. Objective: To examine whether methotrexate has symptom-relieving and disease-modifying effects for participants with knee OA and effusion-synovitis. Design, Setting, and Participants: This multicenter, placebo-controlled randomized clinical trial was conducted at 11 sites in China between July 18, 2019, and January 15, 2023. Community-dwelling patients with inflammatory knee OA with effusion-synovitis on magnetic resonance imaging were included. Interventions: Participants were randomly assigned (1:1) to receive methotrexate, up to 15 mg weekly, or placebo using block randomization, stratified by study site. Main Outcomes and Measures: The primary outcomes were knee visual analog scale (VAS) pain change and effusion-synovitis maximal area change, over 52 weeks in the intention-to-treat population. Results: Of 278 participants screened, 215 participants (mean [SD] age, 60.4 [7.4] years; 191 [89%] female) were randomized (108 to the methotrexate group; 107 to the placebo group), and 175 (81%) completed the trial. Changes in VAS pain and effusion-synovitis maximal area were not significantly different between the methotrexate and placebo group over 52 weeks (between-group difference, 0.3 mm [95% CI, -6.7 to 7.3 mm] for VAS pain; 0.1 cm2 [95% CI, -0.8 to 1.0 cm2] for effusion-synovitis maximal area). No significant between-group differences were found for any of the prespecified secondary outcomes. At least 1 adverse event occurred in approximately 32 participants (29.6%) in the methotrexate group and 26 participants (24.3%) in the placebo group. Conclusions and Relevance: The results of this randomized clinical trial show that, compared to placebo, low-dose methotrexate did not reduce pain or effusion-synovitis over 52 weeks in patients with knee OA and effusion-synovitis. Trial Registration: ClinicalTrials.gov Identifier: NCT03815448.
1
Adverse events occurred in 29.6% of methotrexate-treated participants and 24.3% receiving placebo.
2
In a 215-participant randomized trial, low-dose methotrexate up to 15 mg weekly did not significantly reduce knee pain versus placebo over 52 weeks.
3
Methotrexate did not significantly reduce MRI-measured effusion-synovitis maximal area compared with placebo over 52 weeks.
4
No significant between-group differences were observed for any prespecified secondary outcomes.
5
The trial found no evidence that low-dose methotrexate provides symptom-relieving or disease-modifying benefits for inflammatory knee osteoarthritis with effusion-synovitis.

Inflammatory knee osteoarthritis with MRI-detected effusion-synovitis

The symptom-relieving and disease-modifying effects of low-dose methotrexate on knee pain and effusion-synovitis over 52 weeks

Publication Details
Publication Date
2025-06-02
Journal
Publisher
ISSN
Cited by
28
Access Type
Author Information
Authors
David John Hunter
Flavia Cicuttini
Xiaoxia Li
Xiaofeng Zeng
Zhanguo Li
Yang Xi
Yi Zhao
Zhiyi Zhang
Cibo Huang
Yingjuan Chen
Yifang Mei
Changhai Ding
Jianhua Xu
Weiyu Han
Yunfeng Pan
Xiaotong Zhu
Peihua Cao
Yuan Qu
Zhaohua Zhu
Haowei Chen
Guangfeng Ruan
Qinghong Yu
Xiaomei Leng
Limin Ren
Kun Wang
T W LI
Mei-hua Guan
Jing Wu
Qiuju Liao
Zhe Wang
Zetao Liao
Weiming Deng
Kang Wang
Tingting Zhu
Yuping Zhang
Lixia Gao
Xiaoni Zhou
Yan Zhang
Peichun Gao
Qin Dang
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%